AzTrials
AzTrials

Autism Spectrum Disordere-GOLIAH-ECONCT05271955

e-GOLIAH in Autistic Spectrum Disorders

A study testing "e-GOLIAH" in people with Autism Spectrum Disorder, run by Assistance Publique - Hôpitaux de Paris at 12 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Randomized open-label study comparing children aged 3 to 6 years with autism and normal cognitive development or mild cognitive impairment receiving the usual treatment plus intensive use of eGOLIAH (experimental group) with children receiving only the usual treatment (control group). Read more about this study

Who is it for?
Ages 3 to 6 years
Conditions the study is for
Autism Spectrum Disorder
What is being tested?
"e-GOLIAH"
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
12 sitesFrance
Study dates
15 Jun 2022to 15 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 6 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Child with autism confirmed by a validated instrument (ADI-R or ADOS)
  • Aged 3 to 6 years;
  • Parent(s) agree to get involved in the constraint of using the SG 5 times / week at home for 2 periods of 3 months.
  • Signature of the informed consent form by the 2 holders of parental authority or the only holder of parental authority present
  • Affiliation to a social security scheme (except AME)
  • Non-inclusion criteria :
Show all 13Show fewer
  • Children with behavioral problems;
  • Unstabilized comorbid organic pathology;
  • Moderate and severe cognitive deficit (Intellectual Quotient less than 55);
  • Multi or polyhandicap.
  • Medication that may cause visual or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with the study assessments
  • Degenerative diseases or any other disease that could interfere with the evaluations planned during this study (known epilepsy and/or history of seizures, etc.)
  • Photosensitive persons in order to avoid situations that could induce epileptic seizures in them

Who cannot join

None listed.

Trial locations and contacts

12 sites in 1 country.

David COHEN, Professor, Child Psychiatrist contact

01 42 16 23 51 ext. +33

david.cohen@aphp.fr

12 sites in 1 country

France12 sites
  • Centre Hospitalier d'Amiens

    Amiens, Somme, 80054

    Doctor Xavier BENAROUS, Child Psychiatrist, +33(0)3.22.82.53.63, benarous.xavier@chu-amiens.fr

    Doctor Xavier BENAROUS, Child Psychiatrist

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, Hérault, 34295

    Professor Amaria BAGHDADLI, Child Psychiatrist, +33(0)4.67.33.96.96, a-baghdadli@chu-montpellier.fr

    Professor Amaria BAGHDADLI, Child Psychiatrist

  • Centre Hospitalier Universitaire de Nancy

    Nancy, Meurthe-et-Moselle, 54511

    Professor Bernard KABUTH, Child Psychiatrist, +33(0)3.83.15.45.53, bernard.kabuth@cpn-laxou.com

    Professor Bernard KABUTH, Child Psychiatrist

  • Fondation Lenval - Hôpitaux Pédiatriques de Nice- CHU Lenval

    Nice, Alpes Maritimes, 06200

    Doctor Suzanne THÜMMLER, Child Psychiatrist, +33(0)4.92.03.04.39, thummler.s@pediatrie-chulenval-nice.fr

    Doctor Suzanne THÜMMLER, Child Psychiatrist

  • Assistance Publique - Hôpitaux de Paris, Site de la Pitié-Salpêtrière

    Paris, Île-de-France Region, 75013

    Pr David COHEN, Child Psychiatrist, +33(0)1.42.16.23.51, david.cohen@aphp.fr

    Isabelle MOREAU-BABILAERE, Secretary, +33(0)1.42.16.23.51, isabelle.babilaere@aphp.fr

  • Centre Hospitalier Sainte-Anne / GHU Paris Psychiatrie et Neurosciences

    Paris, Île-de-France Region, 75014

    Doctor Catherine DOYEN, Child Psychiatrist, +33(0)1.45.65.81.24, c.doyen@ch-sainte-anne.fr

    Doctor Catherine DOYEN, Child Psychiatrist

  • Assistance Publique - Hôpitaux de Paris, Site de Necker

    Paris, Île-de-France Region, 75015

    Professor Pauline CHASTE, Child Psychiatrist, +33(0)1.44.49.45.61, pauline.chaste@aphp.fr

    Professor Pauline CHASTE, Child Psychiatrist

  • Centre Hospitalier Universitaire de Paris - Centre Hospitalier d'Henri Laborit

    Poitiers, Vienne, 86021

    Professor Jean XAVIER, Child Psychiatrist, +33(0)5.49.44.57.57, jean.xavier@ch-poitiers.fr

    Professor Jean XAVIER, Child Psychiatrist

  • Centre Hospitalier Universitaire de Strasbourg

    Strasbourg, Bas-Rhin, 67091

    Professor Carmen SCHRÖDER, Child Psychiatrist, +33(0)3.88.11.62.18, schroderc@unistra.fr

    Professor Carmen SCHRÖDER, Child Psychiatrist

  • Centre Hospitalier Universitaire de Toulouse

    Toulouse, Haut-Garonne, 31059

    Professor Jean-Philippe RAYNAUD, Child Psychiatrist, +33(0)5.61.77.60.55, raynaud.jp@chu-toulouse.fr

    Professor Jean-Philippe RAYNAUD, Child Psychiatrist

  • Centre Hospitalier Universitaire de Tours

    Tours, Indre-et-Loire, 37044

    Professor Frédérique BONNET-BRILHAULT, Child Psychiatrist, +33(0)2.47.47.84.12, frederique.brilhault@univ-tours.fr

    Professor Frédérique BONNET-BRILHAULT, Child Psychiatrist

  • Centre Hospitalier de Versailles - André Mignot

    Versailles, Île-de-France Region, 78157

    Professor Mario SPERANZA, Child Psychiatrist, +33(0)1.39.63.85.43, msperanza@ch-versailles.fr

    Professor Mario SPERANZA, Child Psychiatrist

Other trials in France

About this study

Official title: Medico-economic Evaluation of the Care by Serious Games in Outpatient Units and at Home for Children With Autism Spectrum Disorders

Randomized open-label study comparing children aged 3 to 6 years with autism and normal cognitive development or mild cognitive impairment receiving the usual treatment plus intensive use of eGOLIAH (experimental group) with children receiving only the usual treatment (control group).

eGOLIAH (Gaming Open Library for Intervention in Autism at Home) is an accessible online platform for digital games inspired by the principles of the Early Start Denver Model (ESDM), one of the care programs validated in the management of young ASD.

Read more

The duration per patient will be one year. The exposure to e-GOLIAH for the experimental group will be done with the recommendation of intensive exposure to the game (5 sessions> ½ hour per week).

Clinical variables will be assessed at entry, 6 months and 1 year (end of study).

The EQ5D questionnaires will be collected by the supervising therapist during the follow-up visit and at the same time as the clinical variables.

Read the detailed description

In a context of increasing prevalence of Autism Spectrum Disorder (ASD) and the heterogeneity of children's profiles and abilities, early diagnosis is crucial in order to implement intensive, individualized, multidimensional therapeutic care and therefore more efficient. In the context of MICHELANGELO (FP7 European Research project), we developed a serious game called GOLIAH for Gaming Open Library for Intervention for Autism at Home. Using the first beta version as functional prototype, we showed that the demonstrator could be used at home with the help of parents in addition to usual care, during a clinical study including 25 participants. Also, Billeci and colleagues showed that, after training, children's improvement in joint attention tasks was correlated with changes in brain activity and connectivity. We then developed a new version e-GOLIAH to open the opportunity to conduct a large clinical study to assess the validity of the tool in terms of children's improvements. The goals of e-GOLIAH are to bring improvements in terms of ergonomics and accessibility to this initial prototype by finalizing the tool and distributing it to therapists, parents and children with ASD, via the Curapy.com web platform. e-GOLIAH provides, in free and open access, a platform for digital games inspired by the principles of ESDM (Early Start Denver Model) allowing intensive training to improve joint attention and imitation, two key skills for early social interaction and communication. It is a more natural, child-centered intervention method practiced at home and involving parents. This innovative solution takes the assessment and management of autism care out of the usual clinical environment. eGOLIAH (Gaming Open Library for Intervention in Autism at Home) is an accessible online platform for digital games that include ten different games with different level of complexity. A key principle is the collaboration between the child and his/her parent to proceed with the games making it interactive by nature, each participant having his own tablet.

The current study e-GOLIAH-ECO is a medico-economic study powered to recruit 150 children. It is a multisite randomized open-label study comparing children aged 3 to 6 years with autism and normal cognitive development or mild cognitive impairment receiving the usual treatment plus intensive use of eGOLIAH (experimental group) with children receiving only the usual treatment (control group).

The duration per patient will be one year. The exposure to e-GOLIAH for the experimental group will be done with the recommendation of intensive exposure to the game (5 sessions> ½ hour per week).

Clinical variables will be assessed at entry, 6 months and 1 year (end of study). The EQ5D (quality of life) questionnaires will be collected by the supervising therapist during the follow-up visit and at the same time as the clinical variables.

The main objective is to evaluate the 12-month cost-effectiveness of the management of children diagnosed with ASDs using the e-GOLIAH game used at home, compared to usual management.

Secondary objective includes:

(i) To evaluate the cost-effectiveness ratio of the management of patients with ASDs using e-GOLIAH compared to usual management at 12 months of follow-up.

(ii) To explore the remaining ASD-related annual burden of the cost of disease for the two groups studied.

(iii) To evaluate the consequences of the generalization of the management of children diagnosed with ASD using e-GOLIAH, compared to a usual management, from the point of view of the Health Insurance over a period of 3 years.

(iv) To evaluate the impact of the management of children diagnosed with ASD using the e-GOLIAH game used at home, compared to usual management, on the patient's quality of life and that of their responsible parent and the correlation between the two, on adaptive symptoms, on autistic symptoms, on social interactions, on parental stress, at 6 months and at 12 months.

(v) To assess compliance with OS by children and their caregivers. The following scales will be monitored: the EQ5D-3L for quality of life, the Vineland-II scale, the Child Autism Rating Scale (CARS), the Social Responsiveness Scale (SRS), the Parenting Stress Index. In addition the medico-economic data will be monitored from regular interview and social insurance data.

Being tested
"e-GOLIAH", Usual care
Keywords
e-GOLIAH, e-GOLIAH-ECO, Autistic Spectrum Disorders, Children, Tablet, Games, Serious Game
Medical subject headings
Autism Spectrum Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • "e-GOLIAH"Device

    Usual care plus electronic tablet with games application "e-GOLIAH" (Gaming Open Library for Intervention in Autism at Home)

  • Usual careBehavioural

    Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.

Study groups in NCT05271955
Study groupRoleWhat they receive
ExperimentalExperimentalChildren receiving the usual care plus intensive use of e-GOLIAH (experimental group)
Receives: Device: "e-GOLIAH"
ControlActive comparatorChildren receiving only the usual treatment (control group).
Receives: Behavioral: Usual care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of Incremental Cost-Utility Ratio (ICUR) at 12 months between the 2 groups

    ICUR use the 5-level EQ-5D version and the child-friendly EQ-5D version (EQ5D-5L/EQ5D-Y) questionnaires (min score : 0 ; max score : 100 ; higher scores mean a better outcome)

    Measured: 12 months

Secondary outcomes (10)
  1. Comparison of Incremental Cost-utility ratio (ICUR) at 6 months between the 2 groups

    ICUR use the 5-level EQ-5D version and the child-friendly EQ-5D version (EQ5D-5L/EQ5D-Y) questionnaires (min score : 0 ; max score : 100 ; higher scores mean a better outcome)

    Measured: 6 months

  2. Comparison of Incremental cost-effectiveness ratio (ICER) between the 2 groups

    ICER use the Vineland II scale (undetermined minimum and maximum)composite score, average score : 100, higher scores mean a better outcome)

    Measured: 6 and 12 months

  3. Comparison of the out of pocket payment for the consumption of treatments linked to the TSA between the 2 groups

    Amount remaining payable by the patient after deduction of reimbursements received by health insurance

    Measured: 12 months

  4. Budget impact analysis (BIA) of e-GOLIAH in the management of children diagnosed with TSA for health insurance

    Budget impact analysis (BIA) will be measured by direct resources consumed and quantified using the SNIIRAM/SNDS database

    Measured: 3 years

  5. Comparison of Quality of life between the 2 groups

    Measured by the 5-level EQ-5D version and the child-friendly EQ-5D version measured by proxy EQ-5D-5L/EQ-5D-Y(proxy) for the patient and their parent. Scale 0-100 (min score: 0, max score :100, higher scores mean a better outcome)

    Measured: 6 and 12 months

  6. Comparison of Adaptive symptoms between the 2 groups

    Use the Vineland-II Scale of socio-adaptive behavior measured by the composite score with an average to 100 of 4 dimensions: socialization, communication, life skills everyday life, and motricity (undetermined minimum and maximum composite score, average score : 100, higher scores mean a better outcome)

    Measured: 6 and 12 months

  7. Comparison of Autistic symptoms between the 2 groups

    Use the CARS (Child Autism Rating Ladder) scale, 15 items coded from 1 to 4 (score min: 0, max : 60, higher scores mean a worse outcome)

    Measured: 6 and 12 months

  8. Comparison of Social interactions between the 2 groups

    Use the SRS (Social Responsiveness Scale) scale, 65 items coded from 1 to 4 (score min: 0 ; score max : 260, higher scores mean a worse outcome)

    Measured: 6 and 12 months

  9. Comparison of Parental Stress between the 2 groups

    Use the Parental Stress Index scale, 36 items coded from 1 to 5 (score min : 0 ; max: 180, higher scores mean a worse outcome)

    Measured: 6 and 12 months

  10. The child's acceptability to the e-GOLIAH game at home

    interview with clinical team by phone contact every twice a month for 12 months

    Measured: 6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2022
  2. Study start15 Jun 2022 (estimated)
  3. Primary completion15 Dec 2024 (estimated)
  4. Study completion15 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05271955
Sponsor's protocol ID
APHP200052
Other IDs
2020-A03389-30
Acronym
e-GOLIAH-ECO
Status last verified
Feb 2022
First submitted
28 Feb 2022
Last updated
25 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, Donaldson A, Varley J. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics. 2010 Jan;125(1):e17-23. doi: 10.1542/peds.2009-0958. Epub 2009 Nov 30.

    PubMed 19948568
  • Jouen AL, Narzisi A, Xavier J, Tilmont E, Bodeau N, Bono V, Ketem-Premel N, Anzalone S, Maharatna K, Chetouani M, Muratori F, Cohen D; MICHELANGELO Study Group. GOLIAH (Gaming Open Library for Intervention in Autism at Home): a 6-month single blind matched controlled exploratory study. Child Adolesc Psychiatry Ment Health. 2017 Mar 22;11:17. doi: 10.1186/s13034-017-0154-7. eCollection 2017.

    PubMed 28344643
  • Bieleninik L, Geretsegger M, Mossler K, Assmus J, Thompson G, Gattino G, Elefant C, Gottfried T, Igliozzi R, Muratori F, Suvini F, Kim J, Crawford MJ, Odell-Miller H, Oldfield A, Casey O, Finnemann J, Carpente J, Park AL, Grossi E, Gold C; TIME-A Study Team. Effects of Improvisational Music Therapy vs Enhanced Standard Care on Symptom Severity Among Children With Autism Spectrum Disorder: The TIME-A Randomized Clinical Trial. JAMA. 2017 Aug 8;318(6):525-535. doi: 10.1001/jama.2017.9478.

    PubMed 28787504
  • Billeci L, Narzisi A, Tonacci A, Sbriscia-Fioretti B, Serasini L, Fulceri F, Apicella F, Sicca F, Calderoni S, Muratori F. An integrated EEG and eye-tracking approach for the study of responding and initiating joint attention in Autism Spectrum Disorders. Sci Rep. 2017 Oct 19;7(1):13560. doi: 10.1038/s41598-017-13053-4.

    PubMed 29051506
  • Bono V, Narzisi A, Jouen AL, Tilmont E, Hommel S, Jamal W, Xavier J, Billeci L, Maharatna K, Wald M, Chetouani M, Cohen D, Muratori F; MICHELANGELO Study Group. GOLIAH: A Gaming Platform for Home-Based Intervention in Autism - Principles and Design. Front Psychiatry. 2016 Apr 28;7:70. doi: 10.3389/fpsyt.2016.00070. eCollection 2016.

    PubMed 27199777

Questions about this trial

What is this clinical trial studying?

A study testing "e-GOLIAH" in people with Autism Spectrum Disorder, run by Assistance Publique - Hôpitaux de Paris at 12 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact David COHEN, Professor, Child Psychiatrist (01 42 16 23 51 ext. +33, david.cohen@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of Incremental Cost-Utility Ratio (ICUR) at 12 months between the 2 groups (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05271955, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in